How Much Does Ozempic Cost in Georgia in 2026?

Retail Cash Price for Ozempic in Georgia

The manufacturer list price for Ozempic set by Novo Nordisk is $998 per month in 2026, and Georgia retail pharmacies closely mirror that figure. This price applies to all dose strengths (0.25 mg, 0.5 mg, 1.0 mg, and 2.0 mg) because each pen contains a four-week supply regardless of dose tier.

Georgia has no state-mandated drug pricing caps for GLP-1 receptor agonists. Prices at Costco, Kroger, CVS, and Walgreens locations across metro Atlanta, Savannah, and Augusta generally fall within $935 to $1,010 per pen for uninsured patients. The variance depends on individual pharmacy markup and whether the location participates in any discount networks.

For context on what this drug delivers at that price point: in the SUSTAIN-7 trial (N=1,201), semaglutide 0.5 mg reduced HbA1c by 1.5% at 40 weeks versus 1.0% with dulaglutide 0.75 mg, while semaglutide 1.0 mg reduced HbA1c by 1.8% versus 1.4% with dulaglutide 1.5 mg [1]. Weight loss was also significantly greater in the semaglutide arms. These efficacy numbers matter when evaluating whether the monthly price is justified relative to older, cheaper GLP-1 alternatives.

The FDA-approved prescribing information for Ozempic specifies dose escalation starting at 0.25 mg weekly for four weeks, then increasing to 0.5 mg [2]. Patients who need additional glycemic control can escalate to 1.0 mg and then 2.0 mg. Each dose step requires a new prescription, but the monthly cost stays constant at the retail level.

Georgia Medicaid Coverage for Ozempic

Georgia Medicaid covers Ozempic exclusively for type 2 diabetes. Off-label prescribing for weight management is not reimbursed under the state Medicaid program.

This restriction means that Georgia Medicaid beneficiaries prescribed Ozempic must have a documented type 2 diabetes diagnosis with supporting lab values (typically an HbA1c of 7.0% or higher, or a fasting plasma glucose above 126 mg/dL). Prior authorization is required, and the prescriber must demonstrate that metformin alone was insufficient or contraindicated. The Georgia Department of Community Health Preferred Drug List specifies GLP-1 receptor agonists as non-preferred agents requiring step therapy through metformin and often a sulfonylurea before approval.

According to the American Diabetes Association Standards of Care (2024), GLP-1 receptor agonists are recommended as first injectable therapy for patients with type 2 diabetes who have established atherosclerotic cardiovascular disease or high cardiovascular risk [3]. Georgia Medicaid criteria align with this guideline, but the program does not extend coverage to the growing population using semaglutide purely for obesity.

For Georgia Medicaid enrollees seeking weight management, the program does cover lifestyle counseling and, in some managed care plans, orlistat. But branded GLP-1 therapies for obesity (Wegovy, Zepbound) are excluded from Georgia Medicaid formularies as of early 2026.

Insurance Coverage for Ozempic in Georgia

Commercial insurance plans in Georgia cover Ozempic more broadly than Medicaid does, though coverage varies significantly by carrier and plan tier. Anthem Blue Cross, Aetna, Cigna, and UnitedHealthcare all list Ozempic on their Georgia formularies for type 2 diabetes, typically at Tier 3 (preferred brand) or Tier 4 (non-preferred brand).

Copays for commercially insured Georgia patients range from $25 to $150 per month depending on plan design. High-deductible health plans may require full out-of-pocket spending until the deductible is met, meaning some patients pay the $998 list price for January and February before insurance kicks in.

A 2023 analysis published in JAMA Network Open found that among commercially insured adults with type 2 diabetes, out-of-pocket costs for GLP-1 receptor agonists averaged $147 per month, with 18% of patients paying more than $250 per month [4]. Georgia-specific data mirrors national trends.

Employer-sponsored plans through large Georgia employers (Delta Air Lines, Home Depot, UPS) generally offer Tier 3 coverage for Ozempic with prior authorization. Self-insured employer plans can vary widely. The key question for any Georgia patient is whether their specific plan requires prior authorization, step therapy, or quantity limits.

State-regulated small-group and individual plans sold on the Georgia Access marketplace (the state's ACA exchange) must cover diabetes medications as part of essential health benefits. This does not guarantee a specific copay, but it does mean Ozempic cannot be excluded entirely from these plans if prescribed for type 2 diabetes.

The Novo Nordisk Savings Card in Georgia

The Novo Nordisk savings card reduces the out-of-pocket cost for Ozempic to as low as $25 per month for commercially insured patients. It is accepted at all Georgia retail pharmacies. Uninsured patients do not qualify.

Eligibility requirements are straightforward: the patient must have commercial insurance (not Medicare, Medicaid, or Tricare), must be a U.S. resident, and must have a valid Ozempic prescription. The card covers up to $150 per 28-day supply, effectively capping the copay at $25 for most plan designs. Patients with copays exceeding $175 will still pay the difference.

The savings card has a maximum annual benefit. In 2026, the cap is $3,000 per calendar year, which covers roughly 12 months of $25 copays plus $150 in card-subsidized amounts per fill. Patients who reach the cap mid-year revert to their plan's standard copay.

Dr. Robert Gabbay, Chief Scientific and Medical Officer of the American Diabetes Association, has stated: "Cost remains the single largest barrier to GLP-1 receptor agonist adherence, and manufacturer discount programs, while helpful, do not solve the structural affordability problem for the majority of patients" [3].

Georgia patients should activate the savings card at novomedlink.com before filling their first prescription. Pharmacists can process the card as a secondary payer at the point of sale.

Compounded Semaglutide in Georgia: Legality, Cost, and Access

Compounded semaglutide is legal in Georgia when dispensed by a licensed 503A compounding pharmacy with a valid patient-specific prescription. The typical cost is approximately $199 per month, roughly 80% less than brand Ozempic.

This pricing difference exists because 503A compounding pharmacies purchase bulk semaglutide base and compound it into subcutaneous injection form under the Federal Food, Drug, and Cosmetic Act Section 503A. These pharmacies must operate under a prescription from a licensed prescriber, compound for an individual patient, and comply with state Board of Pharmacy regulations. Georgia does not impose additional state-level restrictions beyond federal 503A requirements.

The FDA's guidance on compounding clarifies that compounded drugs are not FDA-approved and do not undergo the same premarket review as branded products [5]. Patients considering compounded semaglutide should understand that batch-to-batch consistency, sterility testing, and potency verification depend on the individual pharmacy's quality systems.

Novo Nordisk has publicly opposed compounded semaglutide, arguing that the drug does not meet the criteria for compounding because it is not in shortage (though the FDA shortage list has fluctuated). As of May 2026, the FDA has removed semaglutide from its official drug shortage list, which has prompted some legal challenges to compounding pharmacies' continued production. Georgia patients should verify with their compounding pharmacy that its semaglutide source and production methods are current with federal enforcement guidance.

Several Georgia-based and Georgia-licensed 503A pharmacies offer compounded semaglutide via telehealth consultation and home delivery. Prices range from $149 to $299 per month depending on dose strength and pharmacy. The $199 figure represents a statewide median for the 0.5 mg to 1.0 mg weekly dose range.

Telehealth Prescribing of Ozempic in Georgia

Georgia law permits telehealth prescribing of Ozempic and compounded semaglutide. No in-person visit is required for the initial prescription.

The Georgia Composite Medical Board recognizes audio-video telehealth encounters as sufficient for establishing a patient-provider relationship, provided the prescriber conducts an appropriate clinical evaluation. Georgia Senate Bill 69 (2023) made permanent the telehealth flexibilities initially enacted during the COVID-19 public health emergency, and prescribers licensed in Georgia (or holding an interstate compact license) can prescribe scheduled and non-scheduled medications via telehealth [6].

Ozempic is not a controlled substance. This simplifies telehealth prescribing because DEA regulations for controlled substances do not apply. A Georgia-licensed physician, nurse practitioner, or physician assistant can evaluate a patient via video, review labs (HbA1c, fasting glucose, BMI), and transmit a prescription to any Georgia pharmacy or to a mail-order pharmacy licensed to operate in the state.

Multiple telehealth platforms now serve Georgia patients specifically for GLP-1 prescribing. Pricing for telehealth consultations ranges from $49 to $199 for the initial visit, with follow-ups typically $29 to $99. Some platforms bundle the consultation fee with the compounded semaglutide cost.

According to a CDC analysis of telehealth utilization, telehealth visits for chronic disease management increased 38-fold between 2019 and 2021 [7]. Post-pandemic adoption has plateaued but remains substantially above pre-2020 levels, particularly for medication management visits that do not require physical examination.

How to Reduce Your Ozempic Cost in Georgia

Georgia patients have five primary strategies for reducing out-of-pocket semaglutide costs, ordered from lowest effort to highest.

Novo Nordisk savings card. Apply online, present at pharmacy. Reduces copay to $25 per month for most commercially insured patients. Takes five minutes.

Compounded semaglutide via 503A pharmacy. Requires a prescription (telehealth or in-person). Costs approximately $199 per month. Not covered by insurance. Patient pays cash directly.

Insurance formulary exceptions. If your plan places Ozempic at Tier 4 or excludes it, your prescriber can submit a formulary exception request citing clinical necessity and prior therapy failure. The Endocrine Society's 2024 guideline on pharmacologic management of obesity supports GLP-1 receptor agonist use in patients with BMI of 30 or above, or 27 or above with comorbidities, which may strengthen exception requests [8].

Patient assistance programs. Novo Nordisk operates the NovoCare Patient Assistance Program for uninsured patients with household income below 400% of the federal poverty level. Qualifying Georgia patients receive Ozempic at no cost. Application requires income documentation and prescriber certification.

Pill form alternative. Oral semaglutide (Rybelsus, 7 mg or 14 mg daily) is sometimes placed at a lower formulary tier than injectable Ozempic. In PIONEER-7, flexible-dose oral semaglutide achieved HbA1c reductions comparable to sitagliptin 100 mg [9]. The oral form may carry a lower copay for patients whose primary goal is glycemic control rather than maximum weight loss.

Ozempic Dose Strengths and Georgia Pharmacy Availability

Georgia retail pharmacies stock all four Ozempic pen configurations: the 0.25 mg/0.5 mg initiation pen, the 1.0 mg pen, and the 2.0 mg pen. Supply disruptions that affected Georgia pharmacies during 2023 and 2024 have largely resolved.

Each pen contains a four-week supply (four doses at the indicated strength). The 0.25 mg/0.5 mg pen is a dual-dose pen used during the first eight weeks of treatment: four weeks at 0.25 mg, then four weeks at 0.5 mg. Patients escalating beyond 0.5 mg receive separate 1.0 mg or 2.0 mg pens.

Storage requirements matter in Georgia's climate. Ozempic pens must be refrigerated (36 to 46 degrees Fahrenheit) before first use. After first use, pens can be stored at room temperature (59 to 86 degrees Fahrenheit) for up to 56 days [2]. During Georgia summers, where temperatures regularly exceed 90 degrees, patients should avoid leaving pens in vehicles or in direct sunlight. Heat exposure degrades the semaglutide peptide and reduces efficacy.

Georgia-Specific Cost Comparison: Brand vs. Compounded vs. Oral

A Georgia patient filling a 12-month semaglutide prescription faces substantially different annual costs depending on the formulation and payment method.

Brand Ozempic (no insurance): $11,976 per year. Brand Ozempic (commercial insurance, Tier 3 copay, no savings card): approximately $1,764 per year. Brand Ozempic (commercial insurance plus Novo Nordisk savings card): approximately $300 per year. Compounded semaglutide (503A, cash pay): approximately $2,388 per year. Oral semaglutide, Rybelsus 14 mg (no insurance): approximately $10,800 per year.

These numbers assume no gaps in therapy, no dose changes mid-year, and consistent monthly pricing. Real-world costs fluctuate with formulary changes, savings card caps, and compounding pharmacy pricing adjustments.

The SUSTAIN trial program demonstrated that semaglutide 1.0 mg produced HbA1c reductions of 1.5% to 1.8% across multiple comparator trials [1]. Whether a patient pays $300 or $11,976 per year, the clinical efficacy of the molecule remains identical when properly dosed and administered. The cost question is purely financial, not pharmacological.

Patients on Georgia Medicaid with type 2 diabetes who receive Ozempic through the prior authorization process pay $0 to $3 per fill, depending on the managed care organization.